Stemline Therapeutics, Inc.

7/20/2010
CEO of Stemline invited to present at Drug Discovery and Development Conference Aug. 4, 2010

3/21/2010
Stemline CEO invited to speak at Cancer Stem Cell conference (Mar. 24-25, 2010)

12/4/2009
Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)

11/30/2009
Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center

7/30/2009
Stemline CEO is invited speaker at New Frontiers in Cancer Drug Development (Aug. 4-6, 2009)

2/5/2009
Nature BioCentury (SciBx) interviews Stemline’s Director of Operations in Notch signaling article

4/9/2008
Stemline Therapeutics raises $12.5 million

12/10/2007
L.A. Times cites Stemline and CEO

5/10/2007
Stemline and CEO cited in Oncology Times article

5/7/2007
Stemline CEO is a panelist and speaker at BIO 2007

3/7/2007
Stemline Therapeutics In-Licenses Phase I Oncology Compound

12/7/2006
Stemline CEO is an invited speaker at the New York Academy of Sciences

9/29/2006
Stemline is awarded a National Institutes of Health STTR grant

1/20/2005
Stemline is cited in New Scientist article

1/18/2005
Stemline is cited in BBC article entitled “Malignant cells targeted in study”

1/17/2005
Stemline licenses high throughput drug discovery technology from University of Cambridge

Printer Friendly

Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center

11/30/2009

M.D. Anderson Cancer Center joins ongoing Phase I/II clinical trial and enters into research collaboration with Stemline

NEW YORK, November 30, 2009/PRNewswire/ -- Stemline Therapeutics, Inc., a private clinical stage biopharmaceutical company and leading developer of oncology compounds directed to cancer stem cells, today announced that the The University of Texas M.D. Anderson Cancer Center (Houston, TX) and Stemline have entered into a research collaboration. As part of this collaboration, M.D. Anderson has joined an ongoing Phase I/II clinical trial of SL-401 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

“We are pleased to be involved with Stemline and its innovative programs targeting cancer stem cells,” said Hagop Kantarjian, MD, Chairman of the Department of Leukemia at M. D. Anderson. “This clinical trial provides a new option for our patients with AML and MDS.”

Stemline’s CEO, Ivan Bergstein, MD, said. “We are very pleased to have M.D. Anderson, a world class institution and leader in oncology, join the ongoing Phase I/II study in AML and MDS for SL-401 and work with us on additional programs. This is an exciting time for the company as we expand our clinical program, advance our diverse pipeline, and continue to build out our proprietary platforms.”

About Stemline Therapeutics, Inc. Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I/II clinical trial. Stemline is also developing a proprietary portfolio of biological and small molecule compounds directed at high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called StemScreen® which the Company has utilized to identify candidate compounds that target cancer stem cells. For more information, please visit the Company’s website at www.stemline.com.

Stemline Contact: Tom Cirrito, PhD Director of Operations Stemline Therapeutics, Inc. Tel: 212-531-5976 Email: tcirrito@stemline.com